Acting FDA Commissioner Janet Woodcock Pushes HHS Inspector General to Open Biogen Investigation
Aduhelm's surprising drug approval continues to make waves throughout the country. In addition to commanding a steep price, a newly [...]
The FDA Unhappy With Biogen’s 9-Year Postmarket Timeline, Asks For Prompt Aduhelm Data
The Food and Drug Administration (FDA)’s approval of Biogen’s Aduhelm is facing widespread criticism, especially after an undisclosed pre-approval meeting [...]
Interview with University of Washington Professor and Dean Sheds Light on Reimbursing Novel Cell and Gene Therapies
The Evidence Base interviewed the University of Washington’s Sean Sullivan on the intricacies of reimbursement for novel therapies. Although these [...]
Recent Publication Considers Outcome-Based Approaches for Rare Disease Therapies
A recent article published in PharmacoEconomics considers outcomes-based approaches that may be used when considering the approval of rare disease [...]
ISMPP Hosts July Webinar on the Value of its CMPP Credential for Medical Publication Professionals
The International Society for Medical Publication Professionals (ISMPP) will hold a webinar on July 21st at 11:00 AM EDT on [...]
The Evidence Base Discusses RWE and HTA Spring Trends
Sreeram Ramagopalan of The Evidence Base discusses real world evidence (RWE) and health technology association (HTA) trends for April and [...]
Upcoming Asia Pacific ISMPP Webinar on Challenges in Publishing RWE Studies and Solutions
The International Society for Medical Publication Professionals (ISMPP) will host a webinar at 9:00 PM EDT on July 14th / [...]
ISPOR Value in Health Article Discusses Generating Cost-Effectiveness Analyses Using US Healthcare Data Based on Age and Disease
ISPOR’s Value in Health has published an article cataloguing healthcare costs and noting that cost-effectiveness analyses may allow for future [...]
Walmart Enters Insulin Industry Amid Criticism
Walmart has announced that it will sell a cheaper version of insulin. Although this move is projected to pass substantial [...]
Upcoming IQVIA Webinar on Optimizing Your Organization’s Approach to RWE
IQVIA will hold a one-hour webinar at 2:00 PM ET on July 22nd on real world evidence (RWE). The webinar [...]
Register Today for ISPOR Webinar on NICE’s Strategic Approach to RWE and Novel Therapy Approval
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR)’s next installment of its Signal series will take place July 15th [...]
Supreme Court to Hear Hospital Drug Pricing Case in Medicare Test
The Supreme Court will hear a case on Medicare drug price determination. This is one of many tests of healthcare [...]
Former HHS Secretary Calls for Investigation into FDA’s Aduhelm Approval
Former Secretary of Health and Human Services (HHS) Donna Shalala has called for an investigation into the widely criticized Aduhelm [...]
Alzheimer’s Association Calls on Biogen to Lower Aduhelm’s Price
The Alzheimer’s Association is the latest group to call on Biogen to lower the price of Aduhelm, its controversial Alzheimer’s [...]
Register Today for IQVIA Webinar on Medicine Use in the United States During the COVID-19 Pandemic and Beyond
The IQVIA Institute will host a webinar to discuss its recent report on medicine use in the United States. The [...]
The Patient Centered Outcomes Research Institute Awards $259 Million in Comparative Effectiveness Research Projects, New Principles Include Utilizing RWD and Improving Equity
The Patient Centered Outcomes Research Institute (PCORI) was established more than a decade ago to improve patient-centered research. The institute provides [...]
ISPOR Announces Associate Chief Science Officer Laura Pizzi, Notes Substantial RWE and HEOR Experience
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) has announced that Laura Pizzi, PharmD, MPH, will assume the position [...]
Artificial Intelligence in Medical Diagnostics Report Now Available, Market Expected to Exceed 3.86 Billion by 2025
The most recent report covering artificial intelligence (AI) in medical diagnostics is now available. The report discusses global market growth, [...]
Aetion Researchers Highlight RWE Best Practices
Aetion researchers discuss their recent article, published in the Journal of Comparative Effectiveness Research. The work is a result of [...]
Biogen’s Aduhelm Price Tag Too High Says ICER
The Institute for Clinical and Economic Review (ICER) published a revised report on Biogen’s Aduhelm. The drug is designed for [...]
AMCP Webinar on RWE Now Available On-Demand
The Academy of Managed Care Pharmacy (AMCP) recently held a webinar on real world evidence (RWE), now available on-demand. The [...]
AMCP Webinar on Biosimilars and RWE Now Available
The Academy of Managed Care Pharmacy (AMCP) held a webinar in late June on biosimilars. A recording of the webinar [...]
GoodRx Study Finds 6,000 Percent Hospital Chargemaster Upcharge for Generic Drugs
GoodRx recently assessed the prices of 12 generic drugs across healthcare systems in the United States. Prices varied widely, with [...]
JMCP Article Highlights Impact of Patient Experience on Value Framework
A recent article, published in the Journal of Managed Care and Specialty Pharmacy (JMCP), discusses how to incorporate the patient [...]
ICER Finds Insufficient Clinical Benefit for Controversial Alzheimer’s Drug in Revised Report and Calls for Price Reduction Ahead of CTAF meeting
The Institute for Clinical and Economic Review (ICER) has issued a revised evidence report on Biogen’s Aduhelm, or aducanumab. ICER [...]